11th IMPACCT RWE Summit 2023

Returning for its 11th year, the IMPACCT: Real World Evidence Summit 2023 will deep dive into the use of RWE for regulatory submissions and clinical trial innovation to unlock unstructured healthcare data and transform disease treatment.

Following exciting FDA and EMA changes, this comprehensive industry-led forum addresses how drug developers can leverage RWE from the beginning to the end of a study, ensuring clinical studies are well-designed, include appropriate protections for their patients and upload data integrity.

Join 100+ senior leaders in RWE, RWD, real world analytics experts and epidemiologists from pharma and biotech to take part in this three-day summit with over 18 hours of exclusive content.

Join your peers to learn how to leverage the new FDA external controls draft guidance to create synthetic control arms using RWE, as well as EHR data and artificial intelligence. Don't miss this unique opportunity to explore how to leverage RWE to target patient populations and drive DE and I into trials.

URLs:
Website: https://go.evvnt.com/1827330-0?pid=10018
Brochure: https://go.evvnt.com/1827330-2?pid=10018
Tickets: https://go.evvnt.com/1827330-3?pid=10018

Prices:
Drug Developer - Conference + Workshop Day: USD 4297.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Workshop Day: USD 3697.00,
Academic - Conference Only: USD 2599.00,
Service Provider - Conference + Workshop Day: USD 5297.00,
Service Provider - Conference Only: USD 3799.00

Speakers: Akshay Vashist, Head of Medical and Real World Data Analytics, Otsuka, Alexander Cole, Executive Director and Global Head of Epidemiology and Real World Science, Alexion Pharmaceuticals, Amit Kulkarni, Head of Heath Economic Modelling and Decision Sciences, Otsuka, Angela Dobes, SVP, Crohn's and Colitis Foundation of America, Aracelis Torres, Senior Vice President, Customer Solutions and Quantitative Sciences, Verana Health, Ashita Batavia, Senior Director - Real-World Evidence, Advanced Analytics Portfolio, Oncology Research and Development, Janssen, Charles Makin, Head Of Global Health Economics ,Outcomes research, Value Access and Pipeline Franchise, Biogen, Danielle Bargo, Director, RWE and US HEOR Lead, Eisai US, Gina Valo, Vice President of Clinical Research Products, Verity Health System, Jeff Wessinger, Vice President and General Manager, Life Sciences, PointClickCare, Jesper Kjær, Director of Data Analytics Centre, Danish Medicines Agency, Kelly Zou, Head of Global Medical Analytics and Real World Evidence, Viatris Inc., Lina Titievsky, Senior Director and Head of Immunology and Opportunistic Epidemiology, GlaxoSmithKline Plc, Megan O'Brien, Associate Vice President, CORE, Merck and Co, Rob Kalesnik-Orszulak, Senior Director, Global Regulatory Strategy, Bristol Myers Squibb, Robertino Mera-Giler, Head of Biostatistics, Epidemiology and Machine Learning, Freenome Inc., Stephanie Watkins, Senior Director - Real World Evidence Inflammation, Gilead Sciences, Stuart Turner, Head of Real World Analytics and Innovation, Rocket Pharmaceuticals Ltd., Sunday Clark, Director - Real-World Evidence Scientist, Pfizer, Vandana Ayyar, Gupta Scientific Advisor, National Institute for Health and Clinical Excellence - NICE, William Blumentals, Head of Pharmacoepidemiology, Specialty Care, Sanofi Genzyme